Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
dc.contributor.author | Peeters, M | |
dc.contributor.author | Price, T | |
dc.contributor.author | Cervantes, A | |
dc.contributor.author | Sobrero, A | |
dc.contributor.author | Ducreux, M | |
dc.contributor.author | Hotko, Y | |
dc.contributor.author | André, T | |
dc.contributor.author | Chan, E | |
dc.contributor.author | Lordick, F | |
dc.contributor.author | Punt, C | |
dc.contributor.author | Strickland, A | |
dc.contributor.author | Wilson, Gregory | |
dc.contributor.author | Ciuleanu, T | |
dc.contributor.author | Roman, L | |
dc.contributor.author | Van Cutsem, E | |
dc.contributor.author | Tian, Y | |
dc.contributor.author | Sidhu, R | |
dc.date.accessioned | 2014-04-17T08:30:20Z | |
dc.date.available | 2014-04-17T08:30:20Z | |
dc.date.issued | 2014-01 | |
dc.identifier.citation | Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. 2014, 25 (1):107-16 Ann Oncol | en |
dc.identifier.issn | 1569-8041 | |
dc.identifier.pmid | 24356622 | |
dc.identifier.doi | 10.1093/annonc/mdt523 | |
dc.identifier.uri | http://hdl.handle.net/10541/315912 | |
dc.description.abstract | The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | en |
dc.title | Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. | en |
dc.type | Article | en |
dc.contributor.department | Department of Oncology, University Hospital Antwerp, Antwerp, Belgium | en |
dc.identifier.journal | Annals of Oncology | en |
html.description.abstract | The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. |